Do you want to read an article? Please log in or register.
Clinical Effectiveness of the Anti-Fibrotic Medications for Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis
RECOMMENDED
Related content
RECOMMENDED
Pulmonary Fibrosis
Adoption of the Anti-Fibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Ann Am Thorac Soc
Dempsey TM, Payne S, Sangaralingham L, Yao X, Shah ND, Limper AH
doi: 10.1513/AnnalsATS.202007-901OC
COMMENTED
Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial
Lancet Respir Med.
Raghu G, Pellegrini CA, Yow E, Flaherty KR, Meyer K, Noth I, Scholand MB, Cello J, Ho LA, Pipavath S, Lee JS, Lin J, Maloney J, Martinez FJ, Morrow E, Patti MG, Rogers S, Wolters PJ, Yates R, Anstrom KJ, Collard HR
doi: 10.1016/
RECOMMENDED
Pulmonary Fibrosis
Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Eur Respir Rev.
Khor YH, Ng Y, Barnes H, Goh NSL, McDonald CF, Holland AE
doi: 10.1183/16000617.0158-2019.
RECOMMENDED
Pulmonary Fibrosis
Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Res.
Holtze CH, Freiheit EA, Limb SL, Stauffer JL, Raimundo K, Pan WT, Flaherty KR, Kim HJ
doi: 10.1186/s12931-020-1315-4.
Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.
Lancet Respir Med
Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, Kardatzke DR, Daigl M, Kirchgaessler KU, Lancaster LH, Lederer DJ, Pereira CA, Swigris JJ, Valeyre D, Noble PW
RECOMMENDED
Pulmonary Fibrosis
Circulating Plasma Biomarkers of Survival in Anti-fibrotic Treated Patients with Idiopathic Pulmonary Fibrosis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Chest.
Adegunsoye A, Alqalyoobi S, Linderholm A, Bowman WS, Lee CT, Pugashetti JV, Sarma N, Ma SF, Haczku A, Sperling A, Strek ME, Noth I, Oldham JM
doi: 10.1016/j.chest.2020.04.066.
RECOMMENDED
Pulmonary Fibrosis
Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
JAMA
Martinez FJ, Yow E, Flaherty KR, Snyder LD, Durheim MT, Wisniewski SR, Sciurba FC, Raghu G, Brooks MM, Kim DY, Dilling DF, Criner GJ, Kim H, Belloli EA, Nambiar AM, Scholand MB, Anstrom KJ, Noth I, CleanUP-IPF Investigators of the Pulmonary Trials Cooperative.
doi: 10.1001/jama.2021.4956
Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis
Respir Res.
Kärkkäinen M, Kettunen HP, Nurmi H, Selander T, Purokivi M, Kaarteenaho R
doi: 10.1186/s12931-017-0642-6.
RECOMMENDED
Interstitial Lung DiseasePulmonary Fibrosis
Prognostic value of transbronchial lung cryobiopsy for the multidisciplinary diagnosis of idiopathic pulmonary fibrosis: a retrospective validation study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med.
Tomassetti S, Ravaglia C, Wells AU, Cavazza A, Colby TV, Rossi G, Ley B, Ryu JH, Puglisi S, Arcadu A, Marchi M, Sultani F, Martinello S, Donati L, Gurioli C, Gurioli C, Tantalocco P, Hetzel J, Dubini A, Piciucchi S, Klersy C, Lavorini F, Poletti V
doi: 10.1016/S2213-2600(20)30122-3.